Examples include EGFR and ALK inhibitors in non-small cell lung cancer, BRAF inhibitors in melanoma, HER2-targeting agents in breast cancer, immune check-point inhibitors of CTLA4 or PD1 in melanoma or non-small cell lung cancer and bevacizumab in patients with radionecrosis of corticosteroid-refractory brain edema [27]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.